A Legal Battle Unfolds
Investors holding shares of Metagenomi, Inc. (NASDAQ: MGX) have the chance to take charge in a securities fraud class action lawsuit against the Company. The law firm Glancy Prongay & Murray LLP (GPM) has extended an invitation to investors with significant losses to lead the charge.
Key Details for Investors
The Class Period for the lawsuit began in February 2024, coinciding with Metagenomi’s IPO. The Lead Plaintiff Deadline is set for November 25, 2024. Those interested in serving as the lead plaintiff can provide their contact information through the official Glancy Prongay & Murray LLP website.
The Allegations Unveiled
According to the complaint, which spans the Class Period, Defendants failed to disclose crucial information to investors. It is alleged that Metagenomi’s partnership with Moderna was not set to continue but rather come to an abrupt end in the near term. Consequently, the lawsuit contends that the positive statements made by Defendants regarding the Company’s business and operations were materially deceptive.
Staying Informed
For further updates on the legal proceedings, investors can follow Glancy Prongay & Murray LLP on LinkedIn, Twitter, or Facebook. Participation in the class action is automatic, and investors can choose to retain their own legal counsel or simply remain a passive member of the lawsuit.
Contact Details
For inquiries about the ongoing class action lawsuit or to understand more about their rights in this matter, interested parties are encouraged to reach out to Charles Linehan, Esquire, of GPM by phone at 310-201-9150 or Toll-Free at 888-773-9224. Correspondence can also be made via email to shareholders@glancylaw.com or by visiting the official Glancy Prongay & Murray LLP website.
